EP1200600A2 - Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine - Google Patents

Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine

Info

Publication number
EP1200600A2
EP1200600A2 EP00956355A EP00956355A EP1200600A2 EP 1200600 A2 EP1200600 A2 EP 1200600A2 EP 00956355 A EP00956355 A EP 00956355A EP 00956355 A EP00956355 A EP 00956355A EP 1200600 A2 EP1200600 A2 EP 1200600A2
Authority
EP
European Patent Office
Prior art keywords
gene
organism
riboflavin
isocitrate dehydrogenase
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00956355A
Other languages
German (de)
English (en)
Inventor
Henning ALTHÖFER
Oskar Zelder
Jose L. Revuelta Doval
Maria Angeles Santos Garcia
Hermann Sahm
Klaus-Peter Stahmann
Ines Maeting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Forschungszentrum Juelich GmbH
Original Assignee
BASF SE
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE, Forschungszentrum Juelich GmbH filed Critical BASF SE
Publication of EP1200600A2 publication Critical patent/EP1200600A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P25/00—Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin

Definitions

  • the present invention relates to a unicellular or multicellular organism for the production of riboflavin.
  • Vitamin B 2 also called riboflavin, is essential for humans and animals.
  • Vitamin B 2 deficiency inflammation of the mucous membranes of the mouth and throat, cracks in the corners of the mouth, itching and inflammation in the skin folds, among other things, skin damage, conjunctivitis, reduced visual acuity and clouding of the cornea. Growth and weight loss may occur in infants and children.
  • Vitamin B 2 is therefore of economic importance, particularly as a vitamin preparation for vitamin deficiency and as a feed additive.
  • it is also used as a food coloring, for example in mayonnaise, ice cream, pudding, etc.
  • Riboflavin is produced either chemically or microbially. In the chemical production processes, riboflavin is usually obtained as a pure end product in multi-stage processes, although relatively expensive starting products - such as D-ribose - must also be used.
  • riboflavin An alternative to the chemical production of riboflavin is the production of this substance by microorganisms.
  • the microbial production of riboflavin is particularly suitable for those cases in which high purity of this substance is not required. This is the case, for example, when the riboflavin is to be used as an additive to feed products. In such cases, the microbial production of riboflavin has the advantage that this substance can be obtained in a one-step process.
  • riboflavin by fermentation of fungi such as Ashbya gossypii or Eremothecium ashbyi is known (The Merck Index, Windholz et al, eds. Merck & Co., page 1 183, 1983, A. Bacher, F. üngens, Augen. Chem. 1969, p. 393); but also yeasts, e.g. Candida or Saccharomyces, and bacteria such as Clostridium, Bacillus and Corynebacterium are suitable for riboflavin production.
  • yeasts e.g. Candida or Saccharomyces
  • bacteria such as Clostridium, Bacillus and Corynebacterium are suitable for riboflavin production.
  • yeast Candida famata methods using the yeast Candida famata are described, for example, in US 05231007.
  • Riboflavin-overproducing bacterial strains are described, for example, in EP 405370, the strains being obtained from Bacillus subtiiis by transforming the riboflavin biosynthesis genes.
  • these prokaryotic genes were unsuitable for a recombinant riboflavin production process using eukaryotes such as Saccharomyces cerevisiae or Ashbya gossypii. Therefore, according to WO 93/03183, genes specific for ribofiavin biosynthesis were derived from a eukaryote. namely from Saccharomyces cerevisiae, in order to provide a recombinant production process for riboflavin in a eukaryotic production organism.
  • such recombinant production processes have little or no success for riboflavin production if the provision of substrate for the enzymes specifically involved in ribofiavin biosynthesis is inadequate.
  • DE 19545468.5 A1 discloses a further process for the microbial production of riboflavin, in which the isocitrate lyase activity or the isocitrate gene expression of a riboflavin-producing microorganism is increased.
  • DE 19840709 A1 discloses a single or multicellular organism, in particular a microorganism for the biotechnical production of riboflavin. This is characterized in that the glycine metabolism is changed in such a way that its riboflavin synthesis without the external supply of glycine is at least equal to that of a wild type of the species Ashbya gossypii ATCC10892.
  • the object of the present invention is accordingly to provide a single-cell or multicellular organism, preferably a microorganism, for the biotechnological production of riboflavin, which enables further optimization of the riboflavin bulking.
  • a microorganism for the biotechnological production of riboflavin, which enables further optimization of the riboflavin bulking.
  • an organism should be made available which enables production which is more economical than the prior art. Above all, the organism should allow increased riboflavin formation compared to previous organisms.
  • This object is achieved by a single-cell or multicellular organism whose enzyme activity is higher than that of a Wiid type of the species Ashbya gossypii ATCC10895 in terms of NAD (P) H formation.
  • the goal of an accelerated intracellular NAD (P) H supply can be achieved by increasing the activity of an NAD (P) H-forming enzyme or reducing the activity of an NAD (P) H consuming enzyme or by changing the specificity.
  • This can be achieved with the known methods of strain improvement of organisms. That is, in the simplest case, corresponding strains can be produced by means of screening according to the selection which is customary in microbiology. The mutation with subsequent selection can also be used. The mutation can be carried out using chemical as well as physical mutagenesis. Another method is selection and mutation with subsequent recombination.
  • the organisms according to the invention can be produced by means of genetic engineering.
  • the organism is modified such that it produces NAD (P) H intracellularly in an amount which is greater than its need for maintaining its metabolism.
  • This increase in intracellular NAD (P) H production can preferably be achieved according to the invention by producing an organism in which the enzyme activity of the isocitrate dehydrogenase is increased. This can be achieved, for example, by increasing the substrate conversion by changing the catalytic center or by canceling the action of enzyme inhibitors.
  • An increased enzyme activity of the isocitrate dehydrogenase can also be brought about by increasing the enzyme synthesis, for example by gene amplification or by switching off factors which repress the enzyme biosynthesis.
  • the isocitrate dehydrogenase activity can preferably be increased by mutating the isocitrate dehydrogenase gene.
  • Such mutations can either be generated undirected using classic methods, such as by UV Irradiation or mutation-triggering chemicals, or specifically by means of genetic engineering methods, such as deletion, insertion and / or nucleotide exchange.
  • Isocstrate dehydrogenase gene expression can be achieved by incorporating isocitrate dehydrogenase gene copies and / or by strengthening regulatory factors which have a positive effect on isocitrate dehydrogenase gene expression.
  • regulatory elements can preferably be strengthened at the transcription level, in particular by increasing the transcription signals.
  • an increase in translation is also possible, for example, by improving the stability of the m-RNA.
  • the isocitrate dehydrogenase gene can be incorporated into a gene construct or into a vector which preferably contains regulatory gene sequences associated with the isocitrate dehydrogenase gene, in particular those which increase gene expression.
  • a ribofiavin-producing microorganism is then transformed with the gene construct containing the isocitrate dehydrogenase gene.
  • the overexpression of the isocitrate dehydrogenase can also be achieved by exchanging the promoter. It is possible to achieve the higher enzymatic activity alternatively by incorporating gene copies or by exchanging the promoter. Equally, however, it is also possible to achieve the desired change in enzyme activity by simultaneously exchanging the promoter and incorporating gene copies.
  • the change in the iso-dehydrogenase gene leads to an accelerated NAD (P) H formation and at the same time to a surprising one high increase in riboflavin formation, which was previously unattainable.
  • the isocitrate dehydrogenase gene is preferably isolated from microorganisms, particularly preferably from fungi. Mushrooms of the Ashbya genus are again preferred. The species Ashbya gossypii is most preferred.
  • all other organisms whose cells contain the sequence for the formation of the isocitrate dehydrogenase are also suitable for isolating the gene.
  • the gene can be isolated by homologous or heterologous complementation of a mutant defective in the isocitrate dehydrogenase gene or by heterologous probing or PCR with heterologous primers.
  • the insert of the complementing plasmid can then be minimized in size by suitable steps with restriction enzymes.
  • PCR Plasmids which carry the fragments thus obtained as an insert are introduced into the! Socitrate dehydrogenase gene defect mutant, which is tested for functionality of the isocitrate dehydrogenase gene.
  • functional constructs are used to transform a riboflavin producer.
  • the isocitrate dehydrogenase genes are available with nucleotide sequences which code for the specified amino acid sequence or its variation. Aliel variations include, in particular, derivatives created by deletion. Insertion and substitution of nucleotides from corresponding sequences are available, the sococitrate dehydrogenase activity being retained. A corresponding sequence is shown in Figure 2b from nucleotide 1 to 1262.
  • a promoter of the nucleotide sequence of nucleotide -661 to -1 according to the iso-cate dehydrogenase genes is in particular.
  • Fig. 1 1 or an essentially identical DNA sequence upstream.
  • the gene can be preceded by a promoter which differs from the promoter with the specified nucleotide sequence by one or more nucleotide exchanges, by insertion and / or deietion, but without the functionality or the effectiveness of the promoter being impaired.
  • the effectiveness of the promoter can be increased by changing its sequence or can be completely replaced by effective promoters.
  • Regulatory gene sequences or regulator genes can also be assigned to the isocitrate dehydrogenase gene, which in particular increase the isocitrate dehydrogenase gene activity. So-called “enhancers” can be assigned to the isocitrate dehydrogenase gene, for example, which bring about increased isocitrate dehydrogenase expression via an improved interaction between RNA polymerase and DNA.
  • One or more DNA sequences can be connected upstream and / or downstream of the isocitrate dehydrogenase gene with or without an upstream promoter or with or without a regulator gene, so that the gene is contained in a gene structure.
  • plasmids or vectors are obtainable which contain the isocitrate dehydrogenase gene and are suitable for transforming a riboflavin producer.
  • the cells obtainable by transformation contain the gene in a replicable form, ie in additional copies on the chromosome, the gene copies by homologous recombination can be integrated at any point in the genome and / or on a plasmid or vector.
  • the single-cell or multi-cell organisms obtained according to the invention can be any cells that can be used for biotechnical processes. These include, for example, fungi, yeasts, bacteria, and plant and animal cells. According to the invention, it is preferably transformed cells from fungi, particularly preferably from fungi of the genus Ashbya.
  • the Ashbya gossypii species is particularly preferred.
  • the isocitrate dehydrogenase (IDP3) gene was cloned by PCR and then sequenced (see Figure 11 for sequence).
  • the partial deletion of the gene by genetic engineering by exchange mutagenesis with a geneticin resistance gene (FIG. 1) was confirmed by Southern blot (FIG. 2).
  • This disruption, i.e. Destruction of the gene in the genome of the fungus means that the fungus can no longer form the isocitrate dehydrogenase encoded by it.
  • FIG. 3 shows the decrease in enzyme activity in the disruption strain Ag ⁇ DP3b in comparison to the wild type ATCC 10895. It was possible to show in preparations of the peroxisomes that this enzyme is localized in these organelles (FIG. 10). While the enzyme activity is clearly measurable in wild-type peroxisomes, there is no more activity in the peroxisomes of the disruption strain.
  • Fig. 7 shows that in the metabolism of unsaturated fatty acids, NADPH is required as a reducing agent in two of three alternative reaction pathways.
  • the 2,4-dienoyl-CoA reductase involved in this could also be localized in peroxisomes in cells from Ashbya (FIG. 8).
  • Disruption of the IDP3 gene should now lead to reduced cell growth on linoleic acid or linolenic acid. This could also be measured (Fig. 9). This shows that the importance of SDP3 for cell metabolism lies in the formation of NADPH.
  • Fig. 1 Scheme of the construction of the vector plDPkan for the gene exchange of the chromosomal AglDP3 gene against a gene copy inactive by deletion and insertion of the G418 R gene.
  • Fig. 2 Checking the partial deletion and simultaneous insertion of the geneticin resistance cassette at the> 4g7DP locus by means of Southern blot analysis. Genomic, Sp ⁇ I-digested DNA was hybridized with a digoxygenin-labeled probe.
  • Fig. 3 Comparison of the enzyme activities of the NADP-specific ICDH of the yAs ⁇ oya wild type, the mutant A.g. ⁇ / DP3b and the AglDP overexpressors A.g. pAGIDP3a and A.g. pAGIDP3b when growing on complete glucose medium.
  • Fig. 4 Comparison of growth and riboflavin formation from and the mutant Ag ⁇ / DP3b when growing on complete soybean oil medium.
  • Figure 5 Comparison of growth, riboflavin formation and NADP-specific Ashbya wild-type ICDH and the y g / DP3 overexpressed A.g. pAGIDP3a and A.g. pAGIDP3b when cultivated on soybean oil full medium.
  • Fig. 7 Degradation pathways of unsaturated fatty acids with double bonds on even (A) and odd (B, C) C atoms in peroxisomes according to Henke he al. (1998).
  • Fig. 9 Comparison of radial growth of ⁇ soya wild type, the mutants A.g. AlDP3a and A.g. ⁇ / DP3b and the overexpressors A.g. pAGIDP3a and A.g. pAGIDP3b on various fatty acids (A: 18: 1 cis9; b: 18: 2 cis9,12; C: 18: 3 cis9,12,15).
  • Fig. 10 Distribution of the enzymes catalase and ICDH in the Percoll density gradient after centrifugation of organelles from mycelium

Abstract

La présente invention concerne un organisme unicellulaire ou pluricellulaire, notamment un micro-organisme, destiné à la production biotechnologique de riboflavine. Son activité enzymatique par rapport à la formation de la NAD(P)H est supérieure à celle d'un type sauvage de la souche Ashbya gossypii ATCC10895.
EP00956355A 1999-08-09 2000-07-31 Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine Withdrawn EP1200600A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19937548 1999-08-09
DE19937548A DE19937548A1 (de) 1999-08-09 1999-08-09 Ein- oder mehrzellige Organismen zur Herstellung von Riboflavin
PCT/EP2000/007370 WO2001011052A2 (fr) 1999-08-09 2000-07-31 Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine

Publications (1)

Publication Number Publication Date
EP1200600A2 true EP1200600A2 (fr) 2002-05-02

Family

ID=7917735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00956355A Withdrawn EP1200600A2 (fr) 1999-08-09 2000-07-31 Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine

Country Status (7)

Country Link
EP (1) EP1200600A2 (fr)
JP (1) JP2003506090A (fr)
KR (1) KR20020033757A (fr)
CN (1) CN1369013A (fr)
AU (1) AU6833100A (fr)
DE (1) DE19937548A1 (fr)
WO (1) WO2001011052A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2164975E (pt) 2007-07-06 2012-03-08 Basf Se Processo para a produção de uma solução aquosa de glicose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066486C (zh) * 1989-06-22 2001-05-30 霍夫曼-拉罗奇有限公司 高产核黄素的细菌菌株
ES2160829T3 (es) * 1995-07-13 2001-11-16 Basf Ag Procedimiento para la obtencion de riboflavina por medio de microorganismos con actividad de isocitratoliasa modificada.
EP0927761A3 (fr) * 1997-12-23 2001-09-05 Basf Aktiengesellschaft Gènes de la synthèse de purine et utilisation pour la production microbienne de riboflavine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0111052A2 *

Also Published As

Publication number Publication date
KR20020033757A (ko) 2002-05-07
DE19937548A1 (de) 2001-03-29
WO2001011052A2 (fr) 2001-02-15
CN1369013A (zh) 2002-09-11
WO2001011052A3 (fr) 2001-07-05
JP2003506090A (ja) 2003-02-18
AU6833100A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
DE69832624T2 (de) Hefestämme zur herstellung von milchsäure
EP0751995B1 (fr) Biosynthese de la riboflavine dans des champignons
WO2012104243A1 (fr) Procédé de préparation de 2,3-butanediol par fermentation
WO2012104234A1 (fr) Procédé de préparation de 2,3-butanediol par fermentation
DE69931162T2 (de) Metabolisch veränderte mikrobiellen zelle mit veränderten metabolitherstellung
EP0722500B1 (fr) Genes permettant le metabolisme de la butyrobetaine/crotonobetaine-l-carnitine et leur utilisation pour la production microbiologique de l-carnitine
EP1015597B1 (fr) Procede de preparation d'ergosterol et de ses produits intermediaires a l'aide de levures recombinees
WO1998029538A2 (fr) Gene de l'adenylate cyclase et son utilisation
EP0839211B1 (fr) Procede de production de riboflavine au moyen de micro-organismes a activite d'isocitratlyase modifiee
DE60313631T2 (de) Produktion von zeaxanthin und beta-cryptoxanthin durch phaffia
WO2001011052A2 (fr) Organismes unicellulaires ou pluricellulaires destines a la production de riboflavine
EP0930367B1 (fr) Champignons du genre Ashbya pour la préparation de riboflavine
EP1472355A1 (fr) Procede de production de zymosterol et/ou de ses produits intermediaires et/ou secondaires biosynthetiques dans des organismes transgeniques
EP2379721A1 (fr) Production améliorée d'acides et de solvants dans des micro-organismes
DE10333144B4 (de) Verfahren zur biotechnologischen Herstellung von Citronensäure mit einer genetisch veränderten Hefe Yarrowia lipolytica
WO2006136311A1 (fr) Genie metabolique de la production de q10 dans des levures de l'espece sporidiobolus
EP0285949B1 (fr) Unité d'expression génétique, et système de clonage et d'expression
EP1918379A1 (fr) Vecteurs d'expression pour l'intégration multiple de gène et l'expression des protéines homologues et hétérologues en levures de l'espèce Arxula
DE19840709A1 (de) Ein- oder mehrzellige Organismen zur Herstellung von Riboflavin
DE60133396T2 (de) Modifizierte zellen und ihre verwendungen, insbesondere zur herstellung von steroidderivate
EP1606390A1 (fr) Procede de production de ergosta-5,7-dienol et/ou de ses produits intermediaires et/ou produits reactionnels biosynthetiques dans des organismes transgeniques
DE60126767T2 (de) Neuartige (r)-2-hydroxy-3-phenylpropionat (d-phenyllaktat) dehydrogenase und für diese kodierendes gen
DE10220234A1 (de) Verfahren sowie Mikroorganismen zur mikrobiellen Herstellung von Pyruvat aus Kohlenhydraten sowie Alkoholen
EP1133570A1 (fr) Organismes pour la preparation extracellulaire de riboflavine
DE19826821B4 (de) Verfahren zur Produktion von Steroidhormonen mittels rekombinanter Spalthefen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20011218;SI PAYMENT 20011218

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FORSCHUNGSZENTRUM JUELICH GMBH

Owner name: BASF AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20040527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050621